News & events

News & events

Filter by:
  • NewsScientific publications

VarmX announces publication of non-clinical safety, toxicokinetic and pharmacodynamic data for VMX-C001 in Pharmaceutics

Key Highlights The peer-reviewed study, published in Pharmaceutics (MDPI), describes the non-clinical safety pharmacology, toxicokinetics and pharmacodynamics of VMX-C001 in...

  • News

VarmX announces reltodecacog alfa (Relto) as the adopted non-proprietary name for VMX-C001

Adopted USAN: Reltodecacog alfa has been adopted by the United States Adopted Names (USAN) Council as the non-proprietary name for...

  • Scientific publications

Preclinical safety and toxicokinetics of VMX-C001 – an intravenous bypassing agent for factor Xa inhibitors

VMX-C001, a modified form of human zymogen factor X, is being developed to stop or prevent bleeding in patients taking...

  • News

VarmX to Present New Data at the 2022 ISTH Congress

VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announced it will...
  • News

First Subjects Dosed in First-in-Human Trial for VarmX’s Anticoagulant Bypassing Agent, VMX-C001

VarmX, a clinical-stage biotech company focusing on development of innovative approaches for the reversal of anticoagulation, today announced treatment of...
  • News

VarmX awarded funding from the EIC Accelerator

VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, has been awarded up...
  • News

VarmX to Present New Data on Lead Compound, VMX-C001, at the ISTH 2021 Virtual Congress

VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces that new...
  • News

VarmX appoints Dr. Jan Öhrström as CEO, and Dr. Alex Gold to Supervisory Board

VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces the appointment...
  • News

VarmX appoints Dr. Gerard Short as Chief Medical Officer

VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces the appointment...
  • Scientific publications

VMX-C001 is a Bypassing Agent for FXa-inhibiting DOACs and Displays a Favorable Pharmacokinetic and Pharmacodynamic Profile

Reversal of anticoagulation is important for safe usage of oral factor (F)Xa-inhibiting direct oral anticoagulants (FXa-DOACs).

...
  • News

VarmX raises € 32 million series B financing

VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces the completion...

VMX-C001: Transforming the treatment of bleeding in patients taking Factor Xa DOACs

Portfolio